Hepatitis

  • Most Topular Stories

  • Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow

    MedWorm: Hepatitis B
    30 Sep 2014 | 4:00 pm
    Summary Chronic hepatitis B virus (HBV) infection may progress to cirrhosis, hepatocellular carcinoma (HCC) and end‐stage liver failure with time. Interruption of this process can only be achieved through effective antiviral treatment. This approach has so far involved the use of immunomodulators such as pegylated interferon alpha (Peg‐IFNα) for a finite period of up to a year and nucleos‐(t)ide analogues (NUCs) for treatment over much longer periods of time. The latter act by suppressing HBV replication at the level of DNA synthesis by inhibiting the viral reverse transcriptase/DNA…
  • Cirrhosis: What You Need To Know

    About.com Hepatitis: What's Hot Now
    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    Cirrhosis of the Liver is extensive scarring, often caused by alcoholism or viral hepatitis, that starts to interfere with normal liver functions. Here are answers to five common questions about cirrhosis and links to more information.
  • Lymph Nodes: Filter Stations for Lymph

    About.com Hepatitis: Most Popular Articles
    1 Oct 2014 | 5:27 am
    Lymph nodes contain large amounts of lymphocytes, a type of white blood cells that attack microbes. Page 7.
  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Hepatitis Central
    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
  • LouisianaBio Launches Statewide Membership Drive

    Hepatitis News
    1 Oct 2014 | 11:43 am
    NEW ORLEANS, LA, USA, October 1, 2014 /EINPresswire.com/ -- LouisianaBio today announced that it is looking for “a few good members” who want to work together to expand the growth of the biosciences industry in Louisiana. LouisianaBio is the state …
 
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • Cirrhosis: What You Need To Know

    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    Cirrhosis of the Liver is extensive scarring, often caused by alcoholism or viral hepatitis, that starts to interfere with normal liver functions. Here are answers to five common questions about cirrhosis and links to more information.
  • Chronic Hepatitis B Drugs

    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    Chronic hepatitis B has several approved drugs for treatment. Here are hepatitis B drugs and some of their pros and cons.
  • Everything You Need to Know About Hepatitis

    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    What is hepatitis? Learn the basics of hepatitis and understand the major symptoms, diagnostic testing and treatments associated with the disease.
  • Can I Donate Blood if I Have Hepatitis?

    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    If you had any kind of viral hepatitis, or unexplained jaundice, at any time since you were age 11, you're not able to donate blood.
  • 10 Complications of Hepatitis

    hepatitis.guide@about.com
    1 Oct 2014 | 4:11 am
    Hepatitis can lead to other diseases. While some are rare, some complications, like fibrosis and cirrhosis, are very common. This article identifies some of the most encountered diseases most linked with hepatitis.
 
  • add this feed to my.Alltop

    Hepatitis Central

  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
  • Say it Ain’t So…New Hep C Drug to Surpass $84,000

    The Editors at Hepatitis Central
    15 Sep 2014 | 9:27 am
    Gilead to raise price for new hepatitis C drug above $84,000 By Deena Beasley September 12, 2014 (Reuters) – The next generation version of Gilead Sciences Inc’s $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month. Continue reading this entire article:…
  • How Quickly Can HCV be Eradicated?

    The Editors at Hepatitis Central
    11 Sep 2014 | 9:48 am
    Telaprevir Treatment Decays Hepatitis C Virus Faster in Blood than Liver By Catherine Kolonko | September 10, 2014 A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body. The study was conducted by Andrew Talal, MD, and other researchers at Weill Cornell Medical College in New York City and the findings published in Hepatology. It was the first time scientists traced in real time how the drug…
  • EU Approves Drug That Is Up to 100% Effective Against Hep C

    Nicole Cutler L.Ac.
    4 Sep 2014 | 12:55 pm
    Many Americans were prepping to celebrate Labor Day weekend while Europeans in the Hepatitis C community had something else to rejoice about. Instead of preparing for a barbeque or holiday sale, physicians, patients and researchers in Europe were ecstatic about the August 27, 2014 approval of daclatasvir, Bristol-Myers Squibb’s Hepatitis C virus NS5A inhibitor. Hepatitis C Overview Transmitted via blood-to-blood contact, Hepatitis C is a contagious, viral infection of the liver. Experts estimate that 150 million people are infected with chronic Hepatitis C worldwide, including about 3 to 4…
  • HCV Drug Update: Daklinza Gets Europe Approval

    The Editors at Hepatitis Central
    3 Sep 2014 | 6:45 am
    Bristol-Myers Hepatitis C Treatment Gets Europe Approval Daklinza Drug Combination Has Shown Strong Cure Rates, Company Says By Michael Calia August  27, 2014 European regulators have approved a Bristol-Myers Squibb Inc. BMY +0.22% drug for use in hepatitis C combination treatments, the company said Wednesday. The ruling by the European Commission allows for the drug, Daklinza, to be marketed in all of the European Union’s member states, Bristol said. Continue reading this entire article: http://online.wsj.com/articles/bristol-myers-hepatitis-c-treatment-gets-europe-approval-1409136824
 
  • add this feed to my.Alltop

    Hepatitis C Treatment News

  • LouisianaBio Launches Statewide Membership Drive

    1 Oct 2014 | 11:43 am
    NEW ORLEANS, LA, USA, October 1, 2014 /EINPresswire.com/ -- LouisianaBio today announced that it is looking for “a few good members” who want to work together to expand the growth of the biosciences industry in Louisiana. LouisianaBio is the state …
  • Bramwell’s Lunch Beat: IRS Tax Subsidy Rules Take Another Hit in Court

    1 Oct 2014 | 11:23 am
    … new hepatitis C drug, Sovaldi, which sells for $1,000 a pill, or $84,000 for a typical course of treatment. Although Gilead, the developer of Sovaldi, is …
  • High-Priced Drug Treatments – Worth the Cost?

    1 Oct 2014 | 11:01 am
    … some feathers. Other high-cost treatments for hepatitis c and a rare form of … high cost of drugs may be in the development of innovative financial … July 2014 Forbes op-ed, former FDA Commissioner Dr. Andrew von Eschenbach …
  • Merck completes sale of consumer unit to Bayer

    1 Oct 2014 | 10:09 am
    … makes products including Claritin allergy medication and Coppertone sun-care line, to … to work together to develop and sell drugs that could be used … . Merck agreed to buy hepatitis C drug developer Idenix Pharmaceuticals a month after …
  • Alios’s Corporate Venture Backers Ride RSV (And Hep C) To Big Payday

    1 Oct 2014 | 8:50 am
    … San Francisco, CA-based developer of antiviral drugs, went to … extend to hepatitis C. Alios’s most advanced hepatitis C treatment is also … trial in the fourth quarter of 2014. Those drugs … newly-approved simeprevir (Olysio), a pill like sofosbuvir, racking …
  • add this feed to my.Alltop

    Hepatitis News

  • AbbVie Demonstrates Commitment to Continued Research in Hepatitis C...

    1 Oct 2014 | 9:19 am
    AbbVie announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting , the Annual Meeting of the American Association for the Study of Liver Diseases in Boston, November 7-11, 2014. Abstracts will be presented highlighting results from AbbVie's investigational treatment combining three direct-acting antivirals with or without ribavirin in patients with genotype 1 chronic hepatitis C virus infection.
  • Vitamin D level and sustained virologic response to interferon-based...

    1 Oct 2014 | 5:28 am
    Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. Baseline 25-hydroxyvitamin D [25 D] level has recently been reported to be an independent predictor of sustained virologic response to treatment with pegylated interferon plus ribavirin for chronic hepatitis C virus infection.
  • Amrita Hospital, Kochi flags off medical relief to flood-hit in Kashmir

    30 Sep 2014 | 10:04 pm
    The Kochi-based Amrita Institute of Medical Sciences is sending its disaster management and mobile tele-medicine unit to Kashmir to provide medical care to people affected by the recent floods. The mobile medical facility is equipped with Colour Echo Cardiography, Gastroscopy, Retinal Camera, Ultra Sonography, X-Ray Radiography, Ventilator, Minor Operation Theatre, Delivery Room facility, Electro Cardiography, Light Microscopy, Digital Photography and Bio Chemical Testing with a semi-auto Analyzer to analyse Hepatitis B, Rat Fever or Leptospirosis, etc.
  • Experts warn against use of multi-dose vials in wake of hepatitis C outbreak at colonoscopy clinics

    30 Sep 2014 | 10:36 am
    Practice of giving more than one dose from a larger bottle may play a bigger role in infections than some health-care professionals think.
  • Flu shot season is time to consider other vaccines

    30 Sep 2014 | 10:36 am
    It is that time of year when you should be planning to get your annual flu shot. But many adults believe that after childhood they may not need any other vaccines.
 
  • add this feed to my.Alltop

    Hepatitis Blog

  • Hepatitis A Cluster in Alabama

    Bill Marler
    27 Sep 2014 | 9:29 am
    The Alabama Department of Public Health is investigating three cases of hepatitis A in Clarke County in southwest Alabama. The department says two of the cases involve people who have a history of international travel. The health department says signs of hepatitis A appear 15 to 50 days after exposure and commonly include mild fever, loss of appetite, nausea, vomiting and tiredness. The disease varies in severity from about two weeks to six weeks or more. The department says casual contact, such as at an office or school, does not transmit the virus. The risk increases when people are in…
  • 165 Sick with Hepatitis A Linked to Townsend Farms Organic Antioxidant Blend

    Bill Marler
    25 Sep 2014 | 9:52 pm
    165 people were confirmed to have become ill from hepatitis A after eating ‘Townsend Farms Organic Antioxidant Blend’ in 10 states: Arizona (24), California (80), Colorado (29), Hawaii (8), New Hampshire (1), New Jersey (1), New Mexico (11), Nevada (6), Utah (3), and Wisconsin (2). [Note: The cases reported from Wisconsin resulted from exposure to the product in California, the cases reported from New Hampshire reported fruit exposure during travel to Nevada, and the case reported in New Jersey was a household contact of a confirmed case from Colorado.] Eight of the confirmed cases were…
  • Whataburger Linked to Hepatitis A Scare

    Bill Marler
    21 Aug 2014 | 9:12 pm
    Austin Texas health officials are alerting the public about possible hepatitis A exposure at a Whataburger in Central Austin. A restaurant employee there at the 2800 Guadalupe St. location has been diagnosed with the hepatitis A virus. Hepatitis A is a contagious liver disease that is usually spread when a person ingests something that has been contaminated with the feces of an infected person, including contaminated food or water. Signs and symptoms of hepatitis A can include the following Fever Fatigue Loss of appetite Nausea Vomiting Abdominal discomfort Dark urine Clay-colored bowel…
  • Another Reason for Hepatitis A Vaccines – Your Restaurant Remains Closed

    Bill Marler
    19 Jul 2014 | 5:09 am
    Tortilla Marissa’s, a Mexican restaurant in Fort Collins, CO, will not reopen until August 9 because of the Hepatitis A scare that the restaurant faced at the end of June, according to the Coloradoan. The Larimer County Health Department has advised the owners to keep the restaurant closed that long due to the virus’ relatively long incubation period, which averages 28 days but can last up to 50 days in some cases. The restaurant originally closed on June 27, a day after an employee tested positive for the virus, which has a high risk of being spread when an infected person handles…
  • Another Hepatitis A Scare: Tortilla Marissa’s Restaurant Worker

    Bill Marler
    28 Jun 2014 | 7:46 am
    The Larimer County Department of Health and Environment is advising the public about a possible exposure to hepatitis A virus at the Tortilla Marissa’s restaurant located at 2635 S. College Avenue in Fort Collins. A food worker employed at Tortilla Marissa has tested positive for hepatitis A, a disease that might be passed to others through food directly handled by the employee before any symptoms appeared.  The restaurant is cooperating fully in the investigation and has agreed to voluntarily close until approved by the Department to reopen.  The risk of transmission to others occurred…
  • add this feed to my.Alltop

    HCV New Drug Research

  • AASLD: AbbVie HCV Drug Data (ABT-450/ritonavir, ombitasvir and dasabuvir) To Be Presented

    1 Oct 2014 | 11:31 am
    AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®Data from 25 accepted abstracts include results from:-- AbbVie's investigational treatment in liver transplant recipients with recurrent genotype 1 (GT1) chronic hepatitis C virus (HCV) infection and in GT1 HCV patients with human immunodeficiency virus type 1 co-infection-- Abstracts evaluating AbbVie's investigational treatment combining two direct-acting antivirals with or without ribavirin (RBV) in patients with genotype 4 chronic HCV…
  • Johns Hopkins Experts Say Open Payments Database Casts Shadows, Not Light

    1 Oct 2014 | 5:27 am
    Wednesday, October 1, 2014 Johns Hopkins Experts Say Open Payments Database Casts Shadows, Not Light A federal, public database launched September 30 with the intention of bringing transparency to financial relationships between physicians and industry may instead result in opacity and misinterpretation, according to experts in bioethics, clinical care and public health at Johns Hopkins.In an opinion published in Annals of Internal Medicine to coincide with the launch of the Open Payments database by the Centers for Medicare & Medicaid Services (CMS), the authors take issue with the…
  • Infrequent Development of Resistance in Geno 1-6 HCV-Infected Subjects Treated with Sofosbuvir in Phase 2 and 3 Clinical Trials.

    1 Oct 2014 | 5:08 am
    Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print]Infrequent Development of Resistance in Genotype 1 through 6 HCV-Infected Subjects Treated with Sofosbuvir in Phase 2 and 3 Clinical Trials.Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H8.Author information 1Gilead Sciences, Foster City, CA 94404.2Data First Consulting Inc., Belmont, CA 94002.3University of Auckland, Auckland…
  • Hepatitis C:Drug–drug interaction (DDI) may not be reflected in prescribing information

    1 Oct 2014 | 4:52 am
    Medication use and medical comorbidity in patients with chronic hepatitis C The latest issue of the European Journal of Gastroenterology & Hepatology evaluates the high utilization of drugs with interaction potential in patients with chronic hepatitis C from a US commercial claims database With the advent of the direct-acting antiviral agents, significant drug–drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection.However, little is known about how often patients with HCV infection use medications that may interact with newer…
  • HCV Fall Issue: Gilead's Islands - The Road to Treatment Access

    30 Sep 2014 | 2:26 pm
    The Treatment Action Group’s Hepatitis/HIV Project collaborates with activists, community members, scientists, governments, and drug companies to make safer, more effective and less toxic treatment for viral hepatitis available. The Project forges coalitions with activists worldwide to demand universal access to hepatitis care and treatment. The following HCV related articles were printed online in the fall issue of "TAGline"NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSISDOWNLOAD: This issue of TAGline as a PDFGilead's Islands - The Road to Treatment AccessThe Road…
 
Log in